This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
About
Dosing
Treatment should be initiated and supervised by a healthcare professional experienced in the diagnosis and treatment of alopecia areata.1
The recommended dose is 50mg once daily, to be taken orally with or without food. Capsules should be swallowed whole and should not be crushed, split or chewed, because these methods of administration have not been studied in clinical trials.1
The benefit-risk of treatment should be re-assessed at regular intervals on an individual basis. Consideration should be given to discontinuing Litfulo in patients who show no evidence of therapeutic benefit after 36 weeks.1
Treatment with ritlecitinib should not be initiated in patients with
an absolute lymphocyte count
(ALC) < 0.5 × 103/mm3
or a
platelet count < 100 × 103/mm3
If a dose is missed, patients should be advised to take the dose as soon as possible unless it is less than 8 hours before the next dose, in which case the patient should not take the missed dose. Thereafter, dosing should be resumed at the regular scheduled time.
Renal impairment1
No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate, (eGFR), of 60 to <90 mL/min); moderate renal impairment (eGFR 30 to <60 mL/min) or severe renal impairment (eGFR <30 mL/min). Ritlecitinib has not been studied in patients with end-stage renal disease or in patients with renal transplants, and is therefore not recommended for use in these patients.1
Hepatic impairment1
No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment. Litfulo is contraindicated in patients with severe (Child Pugh C) hepatic impairment.1
Elderly population1
No dose adjustment is required for patients ≥65 years of age. Data are limited in patients ≥65 years of age.1
Paediatric population1
No dose adjustment is required for adolescents 12 to <18 years of age. The safety and efficacy of Litfulo in children under 12 years of age have not yet been established. No data are available.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.